

**Table | Restoration of AR signalling and GR overexpression in resistant CRPC**

Mechanisms	Signalling pathways/Targets	Solutions	References
AR reactivation	AR enhancer (650 kb centromeric)		(Takeda, Spisák et al., 2018)
	Galectin-3		(Dondoo, Fukumori et al., 2017)
	BMI1	PTC209 (BMI1 inhibitor)	(Zhu, Zhao et al., 2018)
	FOXA1/CREB5/AR		(Hwang, Seo et al., 2019)
	IKBKE/Hippo/c-Myc/AR		(Bainbridge, Walker et al., 2020)
	EphB4/c-Myc/AR	EphB4 inhibitors	(Li, Lanman et al., 2020)
	eIF4F		(Liu, Horn et al., 2019)
	STAT3/AR	GPA500	(Thaper, Vahid et al., 2018)
	AR/AR-Vs	Triptolide	(Han, Huang et al., 2017)
	AR	Tetraaryl cyclobutane (CBs)	(Pollock, Wardell et al., 2016)
	AR	ARCC-4/UT-34/IRF8	(Salami, Alabi et al., 2018)
AR splice variants	lncRNA Malat1		(Tummala, Lou et al., 2017; Stone, 2017; Zhao, Wang et al., 2018)
	ACK1/pY88-H4/WDR5/MLL2/AR, AR-V7		(Mahajan, Malla et al., 2017)
	AR-V7	SPT	(Lam, Nguyen et al., 2020)
	AVPR1A		(Zhao, Peacock et al., 2019)
	NK cells/microRNA-34, microRNA-449/AR-V7, EZH2		(Lin, Chou et al., 2017)
	HSP70/STUB1/AR-V7		(Liu, Lou et al., 2018)
	AKR1C3/AR-V7		(Liu, Yang et al., 2019)
	AR-V7	ABT263 (BCL2 protein inhibitor)/IPI-9119 (fatty acid synthase inhibitor)/Luteolin/CDDO-Me/Degarelix	(Zadra, Ribeiro et al., 2019; Naiki-Ito, Naiki et al., 2019; Khurana, Chandra et al., 2020; Cucchiara, Yang et al., 2019)
	c-Myc/AR-Vs, AR-FL	Quilappon (5-Lox inhibitor)	(BaiCao et al., 2019; Monga, Subramani et al., 2020)
	GATA2/AR-FL, AR-Vs		(Chaytor, Simcock et al., 2019)
	BRD4	JQI/I-BET762 (BET inhibitors)	(Asangani, Dommeti et al., 2014; Chan, Selth et al., 2015)

	ZFX/AR-V7		(Cai, Tsai et al., 2018)
	PARP/AR-V7		(Kounatidou, Nakjang et al., 2019)
<b>AR mutations</b>	AR F876L mutation	ASC-J9®/JJ-450	(Joseph, Lu et al., 2013; Korpai, Korn et al., 2013; Wang, Lin et al., 2016)
	F877L, H875Y, ODM-201 T878A/D891H, and T878A/S889G		(Prekovicvan Royen et al., 2016; Borgmann, Lallous et al., 2018; LallousVolik et al., 2016)
<b>GR overexpression</b>	AMFR-11β-HSD2		(Li, Alyamani et al., 2017)
	TLE3		(Palit, Vis et al., 2019)
	PI3K/AKT/GR		(Adelaiye-Ogala, Gryder et al., 2020)
	GR/AR	Z19 (GR/AR dual antagonist)	(Wu, Xie et al., 2019)